Introduction Executive Summary Neurofibromatosis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Neurofibromatosis – DelveInsight’s Analytical Perspective Mid Stage Products (Phase II) • Comparative Analysis NFX-179: NFlection Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis REC 2282: Recursion Pharmaceuticals • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Neurofibromatosis Key Companies Neurofibromatosis Key Products Neurofibromatosis- Unmet Needs Neurofibromatosis- Market Drivers and Barriers Neurofibromatosis- Future Perspectives and Conclusion Neurofibromatosis Analyst Views Neurofibromatosis Key Companies Appendix

Table 1 Total Products for Neurofibromatosis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• NFlection Therapeutics • SpringWorks Therapeutics • Nobelpharma • Shanghai Fosun Pharmaceutical Development Co, Ltd. • Array BioPharma • Recursion Pharmaceuticals • Zhejiang Betta Pharma • Healx • INTiDYN